Nephrocare Healt

Why is Nephrocare Health Services Ltd falling/rising?

As of 22-Jun, Nephrocare Health Services Ltd's stock price is 724.30, down 1.32%. The decline is due to short-term volatility and sector underperformance, despite strong growth metrics and increased investor interest.

As of 22-Jun, Nephrocare Health Services Ltd's stock price is currently at 724.30, reflecting a decrease of 9.7 points or 1.32%. This decline can be attributed to several factors. Despite the stock's strong performance over the past week and month, where it has risen by 1.89% and 19.23% respectively, it has underperformed its sector today by 1.43%. <BR><BR>The stock reached an intraday high of Rs 756.5, but also touched a low of Rs 718.25, indicating volatility within the trading day. The weighted average price suggests that more volume was traded closer to the low price, which may indicate selling pressure. Additionally, while the stock is above its longer-term moving averages, it is below its 5-day moving average, which could signal a short-term bearish trend.<BR><BR>Investor participation has increased, with a notable rise in delivery volume by 140.45% compared to the 5-day average, suggesting some interest in the stock. However, the company's valuation appears expensive with a Price to Book Value of 6.6 and a Return on Equity (ROE) of 6.9, which may deter some investors. <BR><BR>Overall, while Nephrocare Health Services Ltd has shown strong growth metrics and is net-debt free, the current price drop reflects a combination of short-term volatility, sector underperformance, and concerns over valuation.

Which are the latest news on Nephrocare Healt?

Should I buy, sell or hold Nephrocare Health Services Ltd?

What does Nephrocare Healt do?

Nephrocare Health Services Ltd is a small-cap healthcare company that reported net sales of 266 Cr and a net profit of 30 Cr for March 2026. Key metrics include a P/E ratio of 93.00 and a market cap of INR 7,195 Cr.

Overview: <BR>Nephrocare Health Services Ltd operates in the healthcare services industry and is classified as a small-cap company.<BR><BR>History: <BR>The incorporation year is not provided, and there are no status changes mentioned. The latest quarterly results reported are for March 2026, showing net sales and profit.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 266 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 30 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 7,195 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 93.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.31 <BR>Return on Equity: 6.88% <BR>Price to Book: 6.47 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: Not available. <BR>Email: Not available. <BR>Website: Not available.

How big is Nephrocare Healt?

As of 10th June, Nephrocare Health Services Ltd has a market capitalization of 7,195.00 Cr, with net sales of 990.26 Cr and a net profit of 78.01 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Nephrocare Health Services Ltd has a market capitalization of 7,195.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 990.26 Cr, while the sum of Net Profit for the same period is 78.01 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 584.11 Cr, and Total Assets are valued at 975.89 Cr.

Who are the peers of the Nephrocare Healt?

Nephrocare Healt's peers include Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., and Laxmi Dental. Thyrocare Tech. leads with a 1-year return of 61.22%, while Laxmi Dental has the lowest at -48.44%.

Peers: The peers of Nephrocare Healt are Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., Laxmi Dental.<BR><BR>Quality Snapshot: Excellent management risk is observed at Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Thyrocare Tech., while Average management risk is found at Indegene, Vimta Labs, Krsnaa Diagnost., and Laxmi Dental. Below Average management risk is noted for Suven Life Scie. Good growth is seen at Suraksha Diagno. and Laxmi Dental, while Below Average growth is present in Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Krsnaa Diagnost., and the rest. Excellent capital structure is held by Poly Medicure, Vijaya Diagnost., Indegene, Metropolis Healt, Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., and Laxmi Dental, while Below Average capital structure is noted for Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Thyrocare Tech. at 61.22%, while Laxmi Dental has the lowest at -48.44%. Nephrocare Healt's 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include Krsnaa Diagnost., Suraksha Diagno., and Laxmi Dental.